Sofiyeva Nigar, Ekizoglu Seda, Gezer Altay, Yilmaz Handan, Kolomuc Gayretli Tugba, Buyru Nur, Oral Engin
Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey; Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University, School of Medicine, New Haven, CT, USA.
Department of Medical Biology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:116-122. doi: 10.1016/j.ejogrb.2017.04.027. Epub 2017 Apr 18.
This study aimed to investigate the role of telomerase activity in the development of endometriosis-related infertility by evaluation of the serum telomerase in eutopic and ectopic endometrial tissue.
Eutopic endometrium, cystic wall/ovarian cortex, and venous blood were assessed in forty-seven patients. The following groups of patients were identified: females with endometriosis requiring surgical intervention and healthy control females. Patients with histopathologically confirmed endometriosis were further subdivided in the infertile (n=14) and fertile (n=17) groups. Patients who underwent hysterectomy and oophorectomy for benign gynecological conditions were enrolled in the healthy control group (n=16). Telomerase activity was evaluated with three-group, endometriosis-based and fertility-based designs. Analyses were performed regardless the menstrual cycle phase (Phase G), in proliferative (Phase P) (n=22) and secretory phases (Phase S) (n=25). Telomeric Repeat Amplification Protocol PCR was applied for telomerase activity assessment. All statistical analyses were performed with STATA 14.2, GraphPad Prisma 7.01.
In analyses of the eutopic endometrium, with three-group design, a significant difference was not found in Phase G and P (p=0.58 and p=0.33, respectively). However, a statistical difference was shown in Phase S (p=0.008). A significant difference was not established in Phase G, P and S of endometriosis-based design (p=0.35, p=1.0, p=0.13, respectively). No difference was detected in Phase G and P of fertility-based design (p=0.66 and p=0.14, respectively), whereas in secretory phase difference was approved (p=0,049). Telomerase activity was not established in ectopic endometrium and in serum assessment.
Telomerase activity is useless as a biomarker in peripheric blood analysis. The absence of activity in cystic wall approves the high differentiation of endometriosis tissue, what is the possible reason of low malignancy risk. The high rate of telomerase activity in the eutopic endometrium of the infertile group may be considered as a cause of endometriosis-related infertility.
本研究旨在通过评估在位和异位子宫内膜组织中的血清端粒酶,探讨端粒酶活性在子宫内膜异位症相关性不孕发展中的作用。
对47例患者的在位子宫内膜、囊肿壁/卵巢皮质和静脉血进行评估。确定了以下几组患者:需要手术干预的子宫内膜异位症女性和健康对照女性。组织病理学确诊为子宫内膜异位症的患者进一步分为不孕组(n = 14)和生育组(n = 17)。因良性妇科疾病接受子宫切除术和卵巢切除术的患者纳入健康对照组(n = 16)。采用三组、基于子宫内膜异位症和基于生育能力的设计评估端粒酶活性。无论月经周期阶段(G期)如何,均在增殖期(P期)(n = 22)和分泌期(S期)(n = 25)进行分析。应用端粒重复序列扩增协议PCR评估端粒酶活性。所有统计分析均使用STATA 14.2、GraphPad Prisma 7.01进行。
在位子宫内膜分析中,采用三组设计时,G期和P期未发现显著差异(分别为p = 0.58和p = 0.33)。然而,S期显示出统计学差异(p = 0.008)。基于子宫内膜异位症的设计在G期、P期和S期均未建立显著差异(分别为p = 0.35、p = 1.0、p = 0.13)。基于生育能力的设计在G期和P期未检测到差异(分别为p = 0.66和p = 0.14),而在分泌期差异得到证实(p = 0.049)。异位子宫内膜和血清评估中未检测到端粒酶活性。
端粒酶活性在外周血分析中作为生物标志物无用。囊肿壁中无活性证实了子宫内膜异位症组织的高分化,这可能是恶性风险低的原因。不孕组在位子宫内膜中端粒酶活性高可能被视为子宫内膜异位症相关性不孕的一个原因。